← Search & browse all drugs
NERVOUS SYSTEM › ANTIEPILEPTICS › ANTIEPILEPTICS › Other antiepileptics
ganaxolone
N03AX27
Forms & Strengths
- Oral suspension: 50 mg/mL
Adult Dosing
- Not formally evaluated or indicated for adult-specific indications in the provided scope; primarily studied in pediatric populations.
Pediatric Dosing
- CDD-associated seizures (patients >= 2 years): Initial 6 mg/kg BID, titrated weekly by 3 mg/kg/dose up to a maintenance dose of 21 mg/kg BID (max 42 mg/kg/day).
Indications
- Treatment of seizures associated with Cyclin-Dependent Kinase-Like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older.
Mechanism of Action
- Neuroactive steroid GABA-A receptor positive allosteric modulator; acts at both synaptic and extrasynaptic GABA-A receptors to enhance GABAergic inhibition in the central nervous system.
Contraindications
- Known hypersensitivity to ganaxolone or any of its formulation excipients.
Adverse Reactions
- Somnolence
- Sedation
- Fever
- Salivary hypersecretion
- Status epilepticus
Drug Interactions
- Strong CYP3A4 inhibitors (may significantly increase ganaxolone exposure and adverse effects)
- Strong or moderate CYP3A4 inducers (may significantly decrease ganaxolone efficacy)
- CNS depressants and alcohol (may potentiate sedation and respiratory depression)
Curated Content: Needs Vetting Before Put to Clinical Use